In a report released today, Anthony Stoss from Craig-Hallum maintained a Buy rating on Guardant Health (GH – Research Report). The company’s shares closed last Friday at $22.42.
According to TipRanks, Stoss is a 5-star analyst with an average return of 9.8% and a 56.51% success rate. Stoss covers the Technology sector, focusing on stocks such as Digital Turbine, Calamp, and Digi International.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardant Health with a $43.33 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $41.06 and a one-year low of $20.67. Currently, Guardant Health has an average volume of 1.44M.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GH in relation to earlier this year. Last month, Darya Chudova, the CTO of GH bought 6,626.00 shares for a total of $58,308.80.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Guardant Health (GH) Company Description:
Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
